Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 5 Recurrence 4 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hematologic Neoplasms 1

Interventions

Rituximab 41 Cyclophosphamide 23 Peripheral Blood Stem Cell Transplantation 15 Lenalidomide 14 ibrutinib 11 fludarabine phosphate 11 Etoposide 10 Bortezomib 10 Filgrastim 9 Bendamustine Hydrochloride 9 Mycophenolic Acid 8 Melphalan 8 Cytarabine 8 venetoclax 7 fludarabine 7 Whole-Body Irradiation 7 Vincristine 7 Cyclosporine 7 CT-P10 7 Methotrexate 6 obinutuzumab 5 acalabrutinib 5 Doxorubicin 5 Carmustine 5 Carboplatin 5 Biopsy 5 pembrolizumab 4 ibritumomab tiuxetan 4 carmustine, poliferprosan 20 drug combination 4 Tacrolimus 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, Mantle-Cell × tafasitamab × Clear all

NCT06029309 2025-10-06

ZANU-TAFA

University of Miami

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡